From Yahoo Finance: 2025-05-21 08:15:00

Telomir Pharmaceuticals, Inc. announced a $3 million equity financing deal with The Bayshore Trust, involving 1 million restricted shares at $3.00 per share, an 18% premium. The transaction was structured as straight restricted common stock.

Telomir raised $4 million in equity and secured a $5 million credit line through affiliated entities. Their focus is on submitting their IND by year-end and generating early human efficacy data efficiently.

Telomir is advancing two innovative drug candidates: Telomir-1, an age-reversal molecule, and Telomir-Ag2, a stabilized Silver(II) compound to combat drug-resistant infections. Telomir-1 targets five biological drivers of aging and chronic disease and has shown promising results in preclinical models.

Telomir-Ag2, a novel Silver(II) complex, has demonstrated activity against various bacteria strains, including drug-resistant Staphylococcus aureus. Preclinical studies have shown its efficacy and stability, making it a potential breakthrough in antimicrobial treatments.

Read more: Telomir Pharma To Raise $3 Million Via Equity Financing To Fund Its Rare Disease IND